[1] Wout M., Aleman A., Kessels R.P., Laroi F., Kahn R.S.,
Emotional Processing in a Non-Clinical Psychosis-Prone Sample.
Schizophrenia research, 68(2-3): 271-281 (2004).
[5] Inwanna S., Duangchan C., Matthews A.K.,
Effectiveness of Interventions to Promote Medication Adherence in Schizophrenic Populations in Thailand: A Systematic Review.
International Journal of Environmental Research and Public Health, 19(5): 2887 (2022).
[6] Alpert M., Rosenberg S.D., Pouget E.R., Shaw R.J.,
Prosody and Lexical Accuracy in Flat Affect Schizophrenia. Psychiatry research, 97(2-3): 107-118 (2000).
[11] Akamatsu M.,
Current State and Perspectives of 3D-QSAR.
Current topics in medicinal chemistry, 2(12): 1381-1394 (2002).
[13] آلکثیر، الهام؛ عباسیتبار، فاطمه؛
توسعه مدلهای رابطه های کمی ساختار - ویژگی برای پیشبینی حد اشتعالپذیری بالای ترکیبهای آلی،
نشریه شیمی و مهندسی شیمی ایران،
(1)41: 139 تا 151 (1401).
[14] Bultinck P., De Winter H., Langenaeker W., Tollenare J.P., "
Computational Medicinal Chemistry for Drug Discovery", CRC Press (2003).
[16] Meng, L., Ou-Yang Y., Lv F., Song J., Yao J..
Research on the Anti-Tumor Activity of a Novel Aminopeptidase Inhibitor Based on 3D QSAR Model. Letters in Drug Design & Discovery, 19(9): 811-822 (2022).
[17] Pourbasheer E. Amanlou M.,
3D-QSAR Analysis of Anti-Cancer Agents by CoMFA and CoMSIA. Medicinal Chemistry Research, 23(1): 800-809 (2014).
[18] Pourbasheer E. Aalizadeh R.,
3D-QSAR and Molecular Docking Study of LRRK2 Kinase Inhibitors by CoMFA and CoMSIA Methods. SAR and QSAR in Environmental Research, 27(5): 385-407 (2016).
[19] رحمان ستایش، شهربانو؛ طریک، عبدالحلیم؛ زبیدی، رحمان؛
پیش بینی دمای ذوب مایعهای یونی بر پایه آنیون بیس(تریفلورومتیلسولفونیل) ایمید با رویکرد QSPR،
نشریه شیمی و مهندسی شیمی ایران،
(1)39: 149 تا 158 (1399).
[21] El Fadili M., Er-Rajy M., Kara M., Assouguem A., Belhassan A., Alotaibi A., Mrabti N.N., Fidan H., Ullah R., Ercisli S.,
QSAR, ADMET In Silico Pharmacokinetics, Molecular Docking and Molecular Dynamics Studies of Novel Bicyclo (Aryl Methyl) Benzamides as Potent GlyT1 Inhibitors for the Treatment of Schizophrenia. Pharmaceuticals, 15(6): 670-694 (2022).
[22] Marunnan S.M., Pulikkal B.P., Jabamalairaj A., Bandaru S., Yadav M., Nayarisseri A., Doss V.A.,
Development of MLR and SVM Aided QSAR Models to Identify Common SAR of GABA Uptake Herbal Inhibitors used in the Treatment of Schizophrenia. Current neuropharmacology, 15(8): 1085-1092 (2017).
[23] Primi M.C., Maltarollo V.G., Magalhaes J.G., Malta de Sá M., Rangel-Yagui C.O., Trossini G.H.G.,
Convergent QSAR Studies on a Series of NK3 Receptor Antagonists for Schizophrenia Treatment. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(2): 283-294 (2016).
[25] Garcia-Barrantes P.M., Cho H.P., Blobaum A.L., Niswender C.M., Conn P.J., Lindsley C.W.,
Lead Optimization of the VU0486321 Series of mGlu1 PAMs. Part 1: SAR of Modifications to the Central Aryl Core. Bioorganic & medicinal chemistry letters, 25(22): 5107-5110 (2015).
[26] Garcia-Barrantes P.M., Cho H.P., Metts A.M., Blobaum A.L., Niswender C.M., Conn P.J., Lindsley C.W.,
Lead Optimization of the VU0486321 Series of mGlu1 PAMs. Part 2: SAR of Alternative 3-Methyl Heterocycles and Progress Towards an in Vivo Tool. Bioorganic & medicinal chemistry letters, 26(3): 751-756 (2016).
[27] Garcia-Barrantes P.M., Cho H.P., Blobaum A.L., Niswender C.M., Conn P.J., Lindsley C.W.,
Lead Optimization of the VU0486321 Series of mGlu1 PAMs. Part 3. Engineering Plasma Stability by Discovery and Optimization of Isoindolinone Analogs. Bioorganic & medicinal chemistry letters, 26(8): 1869-1872 (2016).
[28] Davis D.C., Bungard J.D., Chang S., Rodriguez A.L., Blobaum A.L., Boutaud O., Melancon B.J., Niswender C.M., Conn P.J., Lindsley C.W.,
Lead Optimization of the VU0486321 Series of mGlu1 PAMs. Part 4: SAR Reveals Positive Cooperativity Across Multiple mGlu Receptor Subtypes Leading to Subtype Unselective PAMs. Bioorganic & Medicinal Chemistry Letters, 32(1): 127724 (2021).
[29] Sebaugh J.,
Guidelines for Accurate EC50/IC50 Estimation. Pharmaceutical statistics, 10(2): 128-134 (2011).
[30] Louis R., "
SYBYL-X Tripos International", St
, USA (2010).
[31] Brown T.,
ChemDraw.
The Science Teacher, 81(2): 67 (2014).
[32] Clark M. Cramer III R.D.,
The Probability of Chance Correlation using Partial Least Squares (PLS). Quantitative Structure‐Activity Relationships, 12(2): 137-145 (1993).
[33] Cramer III R.D., Bunce J.D., Patterson D.E., Frank I.E.,
Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quantitative Structure‐Activity Relationships, 7(1): 18-25 (1988).
[34] Pourbasheer E., Aalizadeh R., Ebadi A., Ganjali M.R.,
3D-QSAR Analysis of MCD Inhibitors by CoMFA and CoMSIA. Combinatorial Chemistry & High Throughput Screening, 18(8): 751-766 (2015).
[35] Abdel-Ilah L., Veljović E., Gurbeta L., Badnjević A.,
Applications of QSAR Study in Drug Design. International Journal of Engineering Research & Technology (IJERT), 6(06): 128-149 (2017).
